Committee for Advanced Therapies (CAT)
GPTKB entity
Statements (51)
Predicate | Object |
---|---|
gptkbp:instanceOf |
scientific committee
|
gptkbp:advises |
on regulatory processes
|
gptkbp:aimsTo |
ensure patient safety
|
gptkbp:collaboratesWith |
other regulatory bodies
|
gptkbp:composedOf |
experts in various fields
|
gptkbp:contributedTo |
regulatory framework for advanced therapies
|
gptkbp:establishedIn |
2009
|
gptkbp:evaluates |
clinical trial data
safety and efficacy of therapies |
gptkbp:facilitates |
stakeholder engagement
|
gptkbp:focusesOn |
advanced therapy medicinal products
|
gptkbp:hasMember |
scientists
clinicians patient representatives regulatory experts |
https://www.w3.org/2000/01/rdf-schema#label |
Committee for Advanced Therapies (CAT)
|
gptkbp:isAvenueFor |
gptkb:European_Medicines_Agency's_Committee_for_Human_Medicinal_Products
|
gptkbp:isFundedBy |
gptkb:European_Union
|
gptkbp:isInvolvedIn |
training programs
policy advocacy public health initiatives international collaborations safety monitoring scientific conferences scientific assessments research funding decisions data sharing initiatives clinical guidelines development stakeholder workshops regulatory science initiatives patient safety assessments product development discussions risk-benefit evaluations therapeutic area evaluations |
gptkbp:isLocatedIn |
gptkb:Amsterdam
|
gptkbp:isResponsibleFor |
guiding advanced therapy regulations
|
gptkbp:issues |
guidelines
|
gptkbp:meets |
regularly
working groups |
gptkbp:monitors |
emerging therapies
|
gptkbp:participatesIn |
public consultations
|
gptkbp:partOf |
gptkb:European_Medicines_Agency
|
gptkbp:provides |
scientific advice
training for assessors input on policy development recommendations for product classification |
gptkbp:publishes |
scientific opinions
|
gptkbp:reviews |
scientific literature
marketing authorization applications |
gptkbp:supports |
innovation in healthcare
|
gptkbp:worksWith |
gptkb:European_Commission
|